Drugs / UNEX-42
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03857841 | Oct 2019 → May 2021 | bronchopulmonary dysplasia | United Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UNEX-42 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03857841 ↗ |
| Modality | Other / unclassified | “UNEX-42 is a preparation of extracellular vesicles” NCT03857841 ↗ |
| Route | Intravenous | “Subjects then received a single IV dose of UNEX-42 at 20 pmol phospholipid/kg body weight, or placebo.” NCT03857841 ↗ |